Metastatic Colorectal Cancers Recruiting Phase 2 Trials for Oxaliplatin (DB00526)

Also known as: Colorectal Cancer Metastatic / Metastatic Colorectal Cancer / Metastatic Colorectal Cancer (MCRC) / Cancer - Metastatic Colorectal / Colorectal Cancer, Metastatic

IndicationStatusPhase
DBCOND0063579 (Metastatic Colorectal Cancers)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03117972Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 LevelsTreatment
NCT03721653FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer PatientsTreatment
NCT04097444CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRCTreatment
NCT04034459FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRCTreatment
NCT01991873Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal CancerTreatment
NCT01858649Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.Treatment
NCT01531595Study of Bevacizumab in Combination With Alternating Xeliri and Xelox in Metastatic Colorectal CancerTreatment
NCT02128425FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal CancerTreatment
NCT02350530FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-typeTreatment
NCT02476045Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino)Treatment
NCT03388190METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatinTreatment
NCT04169347FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal CancerTreatment
NCT03792269Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRCTreatment